Global Gemtuzumab Ozogamicin Overview: AML is the main condition for which Global Gemtuzumab Ozogamicin is used as a targeted cancer therapy. It is a monoclonal antibody-drug conjugate (ADC) that mixes calicheamicin, a cytotoxic agent, with another medication. The monoclonal antibody present in gemtuzumab ozogamicin is engineered to identify and attach itself to CD33, a protein that...